Chip Davis Says Proposed Rebate Rule Would Help Biosimilar Uptake

March 12, 2019
Although the HHS proposal to eliminate rebates is aimed at reducing seniors’ cost sharing by lowering list prices for branded drugs, the proposed rule also could solve the so-called rebate trap that has thwarted biosimilars competition, Association for Accessible Medicines President and CEO Chip Davis said. However, Davis also worries that brands might find a way to use up-front discounts to game formularies, so he would like the government to require that insurers and pharmacy benefit managers place biosimilars and...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.